http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook
-
Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference
-
Eledon reports early diabetes trial results for tegoprubart drug
-
Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at U
-
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results
-
Eledon reports Phase 2 kidney transplant trial results for tegoprubart
-
Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology’s Kidney Week 2025 Annual Meeting
-
Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference
-
Eledon Pharmaceuticals to present kidney transplant trial results at medical meeting
-
Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annu
-
Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association
-
Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025
-
Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results
-
Eledon presents updated kidney transplant drug trial data
-
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
-
Eledon Pharmaceuticals schedules call for kidney transplant study data
-
Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025
-
Eledon to present kidney transplant drug data at medical congress
-
Updated Data from Eledon Pharmaceuticals’ Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025
-
Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City
-
Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City
-
Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results
-
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results
-
Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference
-
Eledon Pharmaceuticals (ELDN) Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human
-
Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human
-
Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference
-
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook
-
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
-
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference
-
Eledon Pharma (ELDN) Announces Positive Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation
-
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigat
-
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
-
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
-
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
-
Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection
-
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
-
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
-
Eledon Pharmaceuticals (ELDN) Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
-
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
-
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
-
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
-
Eledon Pharmaceuticals (ELDN) Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
-
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
-
Eledon Pharmaceuticals (ELDN) Announces $50M Placement at $2.37/sh
-
Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
-
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
-
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
-
Eledon Pharmaceuticals (ELDN) Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
-
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
